1. Signaling Pathways
  2. Apoptosis
  3. Caspase
  4. Caspase Agonist

Caspase Agonist

Caspase Agonists (5):

Cat. No. Product Name Effect Purity
  • HY-W011641
    (±)-Naringenin
    Agonist 98.88%
    (±)-Naringenin is an orally available anti-inflammatory agent that can regulate both acute and chronic inflammation responses, while also showing antioxidant, neuroprotective, liver-protective, and anti-cancer effects. (±)-Naringenin promotes vasodilation in endothelial cells by activating BKCa channels in muscle cells. It also exerts protective effects against experimental colitis by inhibiting Toll-like receptor 4/NF-κB signaling, making it useful in studies related to sepsis, fulminant hepatitis, fibrosis, and cancer research.
  • HY-161470
    WS-384
    Agonist 98.23%
    WS-384 is a dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor with oral activity, with IC50 values of 338.79 nM and 14.81 nM, respectively. WS-384 possesses anticancer activity and can cause cell cycle arrest, DNA damage, and induce apoptosis. WS-384 can be used in the research of non-small cell lung cancer (NSCLC).
  • HY-117249
    Sanazole
    Agonist
    Sanazole (AK-2123) is a hypoxic cell radiosensitizer. Sanazole enhances radiation-induced DNA strand breaks. In mouse fibroblast tumors, Sanazole increases nuclear condensation and fragmentation, as well as elevates caspase-3 activity, thereby enhancing radiation-induced apoptosis. These characteristics make Sanazole a promising candidate for research in tumor therapy.
  • HY-155389
    Caspase-3 activator 2
    Agonist
    Caspase-3 activator 2 (Compound 2f) is a caspase 3 activator that induces apoptosis and can be used in cancer research. Caspase-3 activator 2 is cytotoxic to HL-60 cells and K562 cells, with IC50 values of 33.52 μM and 76.90 μM respectively.
  • HY-137225
    HTS07944
    Agonist
    HTS07944 (HTS07944SC, C3) is a potent modulator of laminin receptor (37 LR). HTS07944 (HTS07944SC, C3) possesses anti-cancer activity in PC-3 cells and activates Caspase 3/7.